Effects of omapatrilat in low, normal, and high renin experimental hypertension

American Journal of Hypertension

Volumn 11, Issue 3 I, 1998, Pages 363-372

  Trippodo, Nick C ^a   Robl, Jeffrey A ^a   Asaad, Magdi M ^a   Fox, Maxine ^a   Panchal, Balkrushna C ^a   Schaeffer, Thomas R ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

Angiotensin converting enzyme; Dual metalloprotease inhibitor; Neutral endopeptidase

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENKEPHALINASE INHIBITOR; FOSINOPRILAT; METALLOPROTEINASE INHIBITOR; OMAPATRILAT; RENIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; DRUG POTENCY; EXPERIMENTAL MODEL; HYPERTENSION; INTRAVENOUS DRUG ADMINISTRATION; MEAN ARTERIAL PRESSURE; NONHUMAN; PRIORITY JOURNAL; RAT; SPONTANEOUSLY HYPERTENSIVE RAT; SYSTOLIC BLOOD PRESSURE;

EID: 0031955506     PISSN: 08957061     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0895-7061(97)00404-4     Document Type: Article

References (41)

1. Trippodo NC, Robl JA, Asaad MM, et al: Cardiovascular effects of the novel dual inhibitor of neutral endopeptidase and angiotensin converting enzyme BMS-182657 in experimental hypertension and heart failure. J Pharmacol Exp Ther 1995;275:745-752.
2. French JF, Anderson BA, Downs TR, Dage RC: Dual inhibition of angiotensin-converting enzyme and neutral endopeptidase in rats with hypertension. J Cardiovasc Pharmacol 1995;26:107-113.
3. Fournie-Zaluski MC, Coric P, Thery V, et al: Design of orally active dual inhibitors of neutral endopeptidase and angiotensin-converting enzyme with long duration of action. J Med Chem 1996;39:2594-2608.
4. Fink CA, Carlson JE, McTaggart PA, et al: Mercaptoacyl dipeptides as orally active dual inhibitors of angiotensin-converting enzyme and neutral endopeptidase. J Med Chem 1996;39:3158-3168.
5. Gonzalez W, Fournie-Zaluski MC, Turcaud S, et al: Pharmacology of S21402 (RB105): a dual inhibitor of neutral endopeptidase and angiotensin converting enzyme. Cardiovasc Drug Rev 1996;14:166-184.
6. Seymour AA, Swerdel JN, Abboa-Offei B: Antihypertensive activity during inhibition of neutral endopeptidase and angiotensin converting enzyme. J Cardiovasc Pharm 1991;17:456-465.
7. Margulies KB, Perrella MA, McKinley LJ, Burnett JC Jr: Angiotensin inhibition potentiates the renal response to neutral endopeptidase inhibition in dogs with congestive heart failure. J Clin Invest 1991;88:1636-1642.
8. Pham I, Gonzalez W, Amrani AIKE, et al: Effects of converting enzyme inhibitor and neutral endopeptidase inhibitor on blood pressure and renal function in experimental hypertension. J Pharmacol Exp Ther 1993; 265:1339-1347.
9. Seymour AA, Asaad MM, Lanoce VM, et al: Systemic hemodynamics, renal function and hormonal levels during inhibition of neutral endopeptidase 3.4.24.11 and angiotensin-converting enzyme in conscious dogs with pacing-induced heart failure. J Pharm Exper Ther 1993;266:872-883.
10. Trippodo NC, Fox M, Natarajan V, et al: Combined inhibition of neutral endopeptidase and angiotensin converting enzyme in cardiomyopathic hamsters with compensated heart failure. J Pharmacol Exp Ther 1993; 267:108-116.
11. Trippodo NC, Panchal BC, Fox M: Repression of angiotensin II and potentiation of bradykinin contribute to the synergistic effects of dual metalloprotease inhibition in heart failure. J Pharm Exper Ther 1995;272:1-9.
12. Vera WG, Fournie-Zaluski M-C, Pham I, et al: Hypotensive and natriuretic effects of RB 105, a new dual inhibitor of angiotensin converting enzyme and neutral endopeptidase in hypertensive rats. J Pharm Exper Ther 1995;272:343-351.
13. Gros C, Noël N, Souque A, et al: Mixed inhibitors of angiotensin-converting enzyme (EC 3.4.15.1) and enkephalinase (EC 3.4.24.11): rational design, properties, and potential cardiovascular applications of glycopril and alatriopril. Proc Natl Acad Sci USA 1991;88:4210-4214.
14. Fournié-Zaluski MC, Gonzalez W, Turcaud S, et al: Dual inhibition of angiotensin-converting enzyme and neutral endopeptidase by the orally active inhibitor mixanpril: a potential therapeutic approach in hypertension. Proc Natl Acad Sci USA 1994;91:4072-4076.
15. Robl JA, Sun CQ, Stevenson J, et al: Dual metalloprotease inhibitors: mercaptoacetyl-based fused heterocyclic dipeptide mimetics as inhibitors of angiotensin-converting enzyme and neutral endopeptidase. J Med Chem 1997;40:1570-1577.
16. Liao W, Delaney C, Smith R, et al: Supine mean arterial blood pressure (MAP) lowering and oral tolerance of BMS-186716, a new dual metalloprotease inhibitor of angiotensin converting enzyme (ACE) and neutral endopeptidase (NEP), in healthy male subjects (abst). Clin Pharmacol Ther 1997;61:229.
17. Vesterqvist O, Liao W, Manning JA, et al: Effects of BMS-186716, a new dual metalloprotease inhibitor, on pharmacodynamic markers of neutral endopeptidase (NEP) and angiotensin converting enzyme (ACE) activity in healthy men (abst). Clin Pharmacol Ther 1997;61:230.
18. Wilson SK, Lynch DR, Ladenson PW: Angiotensin II and atrial natriuretic factor-binding sites in various tissues in hypertension: comparative receptor localization and changes in different hypertension models in the rat. Endocrinology 1989;124:2799-2808.
19. Luther RR, Glassman HN, Boger RS: Renin inhibitors in hypertension. Clin Nephrol 1991;36:181-186.
20. Wong PC, Hart SD, Duncia JV, Timmermans PB: Nonpeptide angiotensin II receptor antagonists. Studies with DuP 753 and EXP3174 in dogs. Eur J Pharmacol 1991;202:323-330.
21. Trippodo NC, Frohlich ED: Similarities of genetic (spontaneous) hypertension: man and rat. Circ Res 1981;48:309-319.
22. Folkow B: Physiological aspects of primary hypertension. Physiol Rev 1982;62:347-410.
23. SAS: SAS Technical Report P-229 SAS/STAT Software: changes and enhancements. SAS Institute Inc., Cary, NC, 1992.
24. Cushman DW, Ondetti MA, Gordon EM, et al: Rational design and biochemical utility of specific inhibitors of angiotensin-converting enzyme. J Cardiovasc Pharmacol 1987;10 (supp 7):S17-S30.
25. DeForrest JM, Waldron TL, Harvey C, et al: Fosinopril, a phosphinic acid inhibitor of angiotensin I converting enzyme: in vitro and preclinical in vivo pharmacology. J Cardiovasc Pharmacol 1989;14:730-736.
26. Gohlke P, Linz W, Schölkens BA, et al: Angiotensin-converting enzyme inhibition improves cardiac function. Role of bradykinin. Hypertension 1994;23:411-418.
27. Rubin LE, Levi R: Protective role of bradykinin in cardiac anaphylaxis. Coronary-vasodilating and antiarrhythmic activities mediated by autocrine/paracrine mechanisms. Circ Res 1995;76:434-440.
28. Zhang X, Xie YW, Nasjletti A, et al: ACE inhibitors promote nitric oxide accumulation to modulate myocardial oxygen consumption. Circulation 1997;95:176-182.
29. Laursen JB, Harrison DG: Modulation of myocardial oxygen consumption through ACE inhibitors NO effect? Circulation 1997;95:14-16.
30. Margolius HS: Kallikreins and kinins: some unanswered questions about system characteristics and roles in human disease. Hypertension 1995;26:221-229.
31. Hollister AS, Inagami T: Atrial natriuretic factor and hypertension: a review and metaanalysis. Am J Hypertens 1991;4:850-865.
32. Lefrançois P, Clerc G, Duchier J, et al: Antihypertensive activity of sinorphan. Lancet 1990;336:307-308.
33. Ogihara T, Rakugi H, Masuo K, et al: Antihypertensive effects of the neutral endopeptidase inhibitor SCH 42495 in essential hypertension. Am J Hypertens 1994;7:943-947.
34. Bevan EG, Connell JMC, Doyle J, et al: Candoxatril, a neutral endopeptidase inhibitor: efficacy and tolerability in essential hypertension. J Hypertens 1992;10:607-613.
35. Richards AM, Crozier IG, Espiner EA, et al: Acute inhibition of endopeptidase 24.11 in essential hypertension: SCH 34826 enhances atrial natriuretic peptide and natriuresis without lowering blood pressure. J Cardio Pharm 1992;20:735-741.
36. Richards AM, Wittert GA, Crozier IG, et al: Chronic inhibition of endopeptidase 24.11 in essential hypertension: evidence for enhanced atrial natriuretic peptide and angiotensin II. J Hypertens 1993;11:407-416.
37. Richards AM, Crozier IG, Kosoglou T, et al: Endopeptidase 24.11 inhibition by SCH 42495 in essential hypertension. Hypertension 1993;22:119-126.
38. Erdös EG, Skidgel RA: Neutral endopeptidase 24.11 (enkephalinase) and related regulators of peptide hormones. FASEB J 1989;3:145-151.
39. Richards AM, Wittert GA, Espiner EA, et al: Effect of inhibition of endopeptidase 24.11 on responses to angiotensin II in human volunteers. Circ Res 1992;71: 1501-1507.
40. O'Connell JE, Jardine AG, Davies DL, et al: Renal and hormonal effects of chronic inhibition of neutral endopeptidase (EC 3.4.24.11) in normal man. Clin Sci 1993;85:19-26.
41. Favrat B, Burnier M, Nussberger J, et al: Neutral endopeptidase versus angiotensin converting enzyme inhibition in essential hypertension. J Hypertens 1995;13:797-804.